CancerMAAT-YACCSNCT06150976

MAAT For Young Adult Cancer Survivors

A study testing MAAT-YS in people with Cancer, run by University of Pittsburgh at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 39 years
Conditions the study is for: Cancer
What is being tested?: MAAT-YS
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 7 participants
Where: 3 sitesUnited States
Study dates: 12 Feb 2025to 5 Sep 2025
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 39 years
All sexes
No healthy volunteers
Adult

Who may be able to join

Adults aged 18-39
Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
At least 1 year after completion of treatment including chemotherapy, cancer-free
English fluent
Memory or other cognitive problems attributed to cancer and/or cancer treatment
Score of <10 on the FACT-Cog Impact on Quality of Life Scale
Willing to use telehealth with internet access
Willing to provide informed consent to participation

Who cannot join

Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;
Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59
Severe uncorrected sensory impairment (severe hearing or visual impairment).

Trial locations and contacts

3 sites in 1 country.

United States3 sites

Indiana University School of Medicine
Indianapolis, Indiana, 46202
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105-3678
University of Pittsburgh School of Medicine/UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15213

Other trials in United States

About this study

Official title: Modifying Memory and Attention Adaptation Training (MAAT) For Young Adult Childhood Cancer Survivors

The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.

Read the detailed description

This pilot trial will determine MAAT-YS feasibility, treatment satisfaction and size of effect in self-report and objective measures of neurocognitive function.

Eligible participants will be 9 individuals who were diagnosed with non-central-nervous system (CNS) cancer (including leukemia/lymphoma without known CNS involvement) prior to the age of 18, are at least 1-year from completion of cancer treatment, including chemotherapy.

Participants will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.

If successful, further research is planned with a larger, multi-site randomized controlled trial of MAAT-YS.

Conditions: Cancer
Being tested: MAAT-YS
Keywords: Cancer, cancer survivorship, cancer-related cognitive impairment, CRCI, Cognitive-behavioral therapy, Memory Attention and Adaptation Training
Medical subject headings: Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

MAAT-YSBehavioural
MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.

Study groups in NCT06150976
Study group	Role	What they receive
MAAT-YS Group	Experimental	This group will be treated with the MAAT-YS cognitive-behavioral therapy. Receives: Behavioral: MAAT-YS

What is being measured

The primary outcome is the main question the study is designed to answer.

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Perceived Cognitive Impairments Scale (PCI)
The PCI assesses perceived cognitive function of participants within a timeframe of the previous 7 days. It consists of 18 items with a 5-point Likert-type rating of 0 (Never) to 4 (Several times a day) with a scoring range of 0-72. Scoring instructions indicate items are reverse scored, such that higher scores denote better perceived cognitive function, lower scores, poorer cognitive function.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (1) Verbal Memory (VBM) (recognition memory for words)
CNSVS Verbal Memory (VBM) is a computer-based neuropsychological test of word recognition and memory for words). The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (2) Symbol Digit Coding (SDC) (visual motor processing speed)
CNSVS Symbol Digit Coding (SDC) is a computer-based neuropsychological test of visual motor processing speed. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (3) Stroop Test (ST) (visual motor reaction time, processing speed and visual discrimination)
CNSVS Stroop Test (ST) is a computer-based neuropsychological test of visual motor reaction time, processing speed and visual discrimination. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (4) 4-Part Continuous Performance Test (FPCPT) (sustained attention and working memory)
CNSVS 4-Part Continuous Performance Test (FPCPT) is a computer-based neuropsychological test of sustained attention and working memory. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT visits)

Secondary outcomes (10)

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Impact on Quality-of-Life Scale (IQOL)
The IQOL assesses perceived quality of life impact of cognitive symptoms participants experience within a timeframe of the previous 7 days. It consists of 4 items with a 5-point Likert-type rating of 0 (Not at all) to 4 (Very Much) with a scoring range of 0-16. Scoring instructions indicate items are reverse scored, such that higher scores denote better quality of life, lower scores, poorer quality of life.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Cognitive-Symptom-Checklist-Work-21 (CSC-W-21)
The CSC-W-21 is a 21-tem self-report measure of perceived impact of cognitive symptoms on work (occupational)-related tasks. Respondents are asked to indicate "yes" (1 point) or "no" (0 points) to each item. Higher scores, ranging from 0-21, denote more work-related cognitive symptoms.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Metamemory in Adulthood-Anxiety Scale (MIA-A)
The MIA-A is a 14-item scale that uses a 5-point Likert-type rating for each item (1= Disagree Strongly; 5 Agree Strongly) with item 13 reverse scored. Items are summed with higher scores (range from 14-70) denoting more anxiety associated with perceived cognitive problems in daily life.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety v.1. - Short Form 4a
The PROMIS Anxiety v.1 Short Form 4a scale evaluates self-reported fearfulness, cognitive focus, and concentration, as well as emotional distress related to worry and feeling uneasy over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10).Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more anxiety.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Depression v.1. - Short Form 4a
The PROMIS Depression v.1 Short Form 4a scale evaluates self-reported negative mood, helpless and worthlessness over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more depression.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue v.1. - Short Form 4a
The PROMIS Fatigue v.1 Short Form 4a scale evaluates self-reported symptoms of exhaustion, fatigue and interference with daily activity over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=not at all; 2=a little bit; 3=somewhat; 4=quite a bit; and 5=very much) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more anxiety.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Physical 2a
The PROMIS Global Health Physical scale is a self-report measure assessing physical health and ability. It consists of 2 items with a 5-point Likert-type rating of 1 (Poor) to 5 (Excellent) with a scoring range of 2-10. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote better physical health.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Mental 2a
The PROMIS Global Health Mental scale is a self-report measure assessing mental health and ability. It consists of 2 items with a 5-point Likert-type rating of 1 (Poor) to 5 (Excellent) with a scoring range of 2-10. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote better mental health.
Measured: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Credibility/Expectancy Questionnaire (CEQ)
The CEQ is a self-report measure assessing the credibility and expectancy of treatment received. It consists of 6 items, 4 items with a 9-point Likert-type rating of 1 (not at all) to 5 (very much) with a scoring range of 3-27. The other 2 items are on a percentage scale from 0%-100% in increments of 10 with a scoring range of means 0-100%. Higher scores denote higher treatment credibility and expectancy.
Measured: Only administered after Visit 6 of MAAT-YS (after 6 weeks)
Treatment Satisfaction Questionnaire (TSS)
The Treatment Satisfaction (TSS) questionnaire is a self-report measure assessing satisfaction of treatment. It consists of 5 items with a 5-point Likert-type rating of 0 (not at all) to 8 (completely) with a scoring range of 0-40 and 1 additional yes/no item about whether traveling for treatment is possible for participation. Higher scores denote more satisfaction with treatment.
Measured: Post-MAAT-YS treatment only (8 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

12 Feb 20255 Sep 2025

First posted30 Nov 2023
Study start12 Feb 2025
Primary completion5 Sep 2025
Study completion5 Sep 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for CancerStudies of the same condition, open and under way.
More trials run by University of PittsburghThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 7 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06150976
Sponsor's protocol ID: HCC 23-043
Acronym: MAAT-YACCS
Status last verified: Jan 2026
First submitted: 10 Nov 2023
Last updated: 12 Jan 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: There is no data sharing plan with other institutions for this pilot trial.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer

All Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Modifying Memory and Attention Adaptation Training (MAAT) For Young Adult Childhood Cancer Survivors
ClinicalTrials.gov ID: NCT06150976
Acronym / sponsor ID: MAAT-YACCS / HCC 23-043
Conditions: Cancer
Keywords: Cancer, cancer survivorship, cancer-related cognitive impairment, CRCI, Cognitive-behavioral therapy, Memory Attention and Adaptation Training
Study type: Interventional
Recruitment status: Completed
Enrolment: 7 participants (actual)
Lead sponsor: University of PittsburghUniversity, hospital or other
Collaborators: Indiana University, St. Jude Children's Research Hospital
Study start: 12 Feb 2025 (actual)
Primary completion: 5 Sep 2025 (actual)
Study completion: 5 Sep 2025 (actual)
First posted: 30 Nov 2023 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This pilot trial will determine MAAT-YS feasibility, treatment satisfaction and size of effect in self-report and objective measures of neurocognitive function.

If successful, further research is planned with a larger, multi-site randomized controlled trial of MAAT-YS.

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
MAAT-YS Group	Experimental	Behavioral: MAAT-YSThis group will be treated with the MAAT-YS cognitive-behavioral therapy.

Who may qualify

Ages: 18 to 39 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult

Key inclusion criteria (8 listed)

Adults aged 18-39
Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
At least 1 year after completion of treatment including chemotherapy, cancer-free
English fluent
Memory or other cognitive problems attributed to cancer and/or cancer treatment

Key exclusion criteria (4 listed)

Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;
Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59
Severe uncorrected sensory impairment (severe hearing or visual impairment).

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
MAAT-YSMAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.	Behavioural	MAAT-YS Group

Primary outcome

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Perceived Cognitive Impairments Scale (PCI)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
The PCI assesses perceived cognitive function of participants within a timeframe of the previous 7 days. It consists of 18 items with a 5-point Likert-type rating of 0 (Never) to 4 (Several times a day) with a scoring range of 0-72. Scoring instructions indicate items are reverse scored, such that higher scores denote better perceived cognitive function, lower scores, poorer cognitive function.
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (1) Verbal Memory (VBM) (recognition memory for words)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNSVS Verbal Memory (VBM) is a computer-based neuropsychological test of word recognition and memory for words). The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (2) Symbol Digit Coding (SDC) (visual motor processing speed)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNSVS Symbol Digit Coding (SDC) is a computer-based neuropsychological test of visual motor processing speed. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (3) Stroop Test (ST) (visual motor reaction time, processing speed and visual discrimination)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
CNSVS Stroop Test (ST) is a computer-based neuropsychological test of visual motor reaction time, processing speed and visual discrimination. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.
CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (4) 4-Part Continuous Performance Test (FPCPT) (sustained attention and working memory)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT visits)
CNSVS 4-Part Continuous Performance Test (FPCPT) is a computer-based neuropsychological test of sustained attention and working memory. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.

10 secondary outcomes

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Impact on Quality-of-Life Scale (IQOL)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Cognitive-Symptom-Checklist-Work-21 (CSC-W-21)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Metamemory in Adulthood-Anxiety Scale (MIA-A)
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety v.1. - Short Form 4a
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Depression v.1. - Short Form 4a
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue v.1. - Short Form 4a
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Physical 2a
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Mental 2a
Time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)
Credibility/Expectancy Questionnaire (CEQ)
Time frame: Only administered after Visit 6 of MAAT-YS (after 6 weeks)
Treatment Satisfaction Questionnaire (TSS)
Time frame: Post-MAAT-YS treatment only (8 weeks)

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
Individual participant dataSharing planned: No. There is no data sharing plan with other institutions for this pilot trial.

Related trials for Cancer

Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Robert J Ferguson, PhD principal investigator

St. Jude Children's Research Hospital

Donna Posluszny, PhD principal investigator

University of Pittsburgh

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing MAAT-YS in people with Cancer, run by University of Pittsburgh at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Perceived Cognitive Impairments Scale (PCI) (time frame: Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06150976.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.